ATE314350T1 - Malonsäure derivate, verfahren zu ihrer herstellung, ihre verwendung als inhibitor der faktor xa aktivität und pharmazeutische zusammensetzungen diese enthaltend - Google Patents

Malonsäure derivate, verfahren zu ihrer herstellung, ihre verwendung als inhibitor der faktor xa aktivität und pharmazeutische zusammensetzungen diese enthaltend

Info

Publication number
ATE314350T1
ATE314350T1 AT01907546T AT01907546T ATE314350T1 AT E314350 T1 ATE314350 T1 AT E314350T1 AT 01907546 T AT01907546 T AT 01907546T AT 01907546 T AT01907546 T AT 01907546T AT E314350 T1 ATE314350 T1 AT E314350T1
Authority
AT
Austria
Prior art keywords
inhibitor
factor
activity
production
pharmaceutical compositions
Prior art date
Application number
AT01907546T
Other languages
English (en)
Inventor
Fahad Al-Obeidi
Armin Walser
Peter Wildgoose
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of ATE314350T1 publication Critical patent/ATE314350T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56Amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
AT01907546T 2000-02-26 2001-02-21 Malonsäure derivate, verfahren zu ihrer herstellung, ihre verwendung als inhibitor der faktor xa aktivität und pharmazeutische zusammensetzungen diese enthaltend ATE314350T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00104041A EP1127884A1 (de) 2000-02-26 2000-02-26 Neue Malonsäure Derivaie, Verfahren zu ihrer Herstellung, ihre Verwendung als Inhibitor der Faktor XA Aktivtät und pharmazeutische Zusammensetzungen diese enthaltend
PCT/EP2001/001928 WO2001062735A1 (en) 2000-02-26 2001-02-21 Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor xa activity and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
ATE314350T1 true ATE314350T1 (de) 2006-01-15

Family

ID=8167968

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907546T ATE314350T1 (de) 2000-02-26 2001-02-21 Malonsäure derivate, verfahren zu ihrer herstellung, ihre verwendung als inhibitor der faktor xa aktivität und pharmazeutische zusammensetzungen diese enthaltend

Country Status (23)

Country Link
US (1) US6794365B2 (de)
EP (2) EP1127884A1 (de)
JP (1) JP2003524001A (de)
KR (1) KR20020079892A (de)
CN (1) CN1406226A (de)
AR (1) AR027533A1 (de)
AT (1) ATE314350T1 (de)
AU (1) AU2001235486A1 (de)
BR (1) BR0108694A (de)
CA (1) CA2400871C (de)
CZ (1) CZ20022862A3 (de)
DE (1) DE60116272T2 (de)
ES (1) ES2254370T3 (de)
HK (1) HK1052696A1 (de)
HU (1) HUP0300080A3 (de)
IL (1) IL151459A0 (de)
MX (1) MXPA02007398A (de)
NO (1) NO20024040L (de)
NZ (1) NZ520982A (de)
PL (1) PL357183A1 (de)
RU (1) RU2002125671A (de)
WO (1) WO2001062735A1 (de)
ZA (1) ZA200206581B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224023A1 (en) * 2002-05-29 2003-12-04 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Cosmetic compositions with hydroxy amine salts of malonic acid
US20040185073A1 (en) * 2003-03-17 2004-09-23 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Cosmetic compositions containing salts of malonic acid
US20040185015A1 (en) * 2003-03-17 2004-09-23 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Sunscreen cosmetic compositions storage stabilized with malonate salts
US20040185074A1 (en) * 2003-03-17 2004-09-23 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Odor control in amine salt containing cosmetic compositions
US20040202689A1 (en) * 2003-03-17 2004-10-14 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Terpenoid fragrance components stabilized with malonic acid salts
US9279022B1 (en) 2014-09-08 2016-03-08 Sirrus, Inc. Solution polymers including one or more 1,1-disubstituted alkene compounds, solution polymerization methods, and polymer compositions
US9828324B2 (en) 2010-10-20 2017-11-28 Sirrus, Inc. Methylene beta-diketone monomers, methods for making methylene beta-diketone monomers, polymerizable compositions and products formed therefrom
US9249265B1 (en) 2014-09-08 2016-02-02 Sirrus, Inc. Emulsion polymers including one or more 1,1-disubstituted alkene compounds, emulsion methods, and polymer compositions
US8884051B2 (en) 2010-10-20 2014-11-11 Bioformix Inc. Synthesis of methylene malonates using rapid recovery in the presence of a heat transfer agent
US10414839B2 (en) 2010-10-20 2019-09-17 Sirrus, Inc. Polymers including a methylene beta-ketoester and products formed therefrom
MX370256B (es) 2011-10-19 2019-12-09 Sirrus Inc Monomeros multifuncionales, procedimientos para la preparación de monomeros multifuncionales, composiciones polimerizables y productos formados a partir de los mismos.
JP6553505B2 (ja) 2012-03-30 2019-07-31 シラス・インコーポレイテッド 複合材およびラミネート物品ならびにこれらを作製するための重合系
WO2013149165A1 (en) 2012-03-30 2013-10-03 Bioformix Inc. Methods for activating polymerizable compositions, polymerizable systems, and products formed thereby
CA2869115A1 (en) 2012-03-30 2013-10-03 Bioformix Inc. Ink and coating formulations and polymerizable systems for producing the same
WO2013181600A2 (en) 2012-06-01 2013-12-05 Bioformix Inc. Optical material and articles formed therefrom
WO2014078689A1 (en) 2012-11-16 2014-05-22 Bioformix Inc. Plastics bonding systems and methods
WO2014085570A1 (en) 2012-11-30 2014-06-05 Bioformix, Inc. Composite compositions for electronics applications
CN105008321A (zh) 2013-01-11 2015-10-28 瑟拉斯公司 经过双(羟甲基)丙二酸酯的途径获得亚甲基丙二酸酯的方法
US9416091B1 (en) 2015-02-04 2016-08-16 Sirrus, Inc. Catalytic transesterification of ester compounds with groups reactive under transesterification conditions
US9315597B2 (en) 2014-09-08 2016-04-19 Sirrus, Inc. Compositions containing 1,1-disubstituted alkene compounds for preparing polymers having enhanced glass transition temperatures
US10501400B2 (en) 2015-02-04 2019-12-10 Sirrus, Inc. Heterogeneous catalytic transesterification of ester compounds with groups reactive under transesterification conditions
US9334430B1 (en) 2015-05-29 2016-05-10 Sirrus, Inc. Encapsulated polymerization initiators, polymerization systems and methods using the same
US9217098B1 (en) 2015-06-01 2015-12-22 Sirrus, Inc. Electroinitiated polymerization of compositions having a 1,1-disubstituted alkene compound
US9518001B1 (en) 2016-05-13 2016-12-13 Sirrus, Inc. High purity 1,1-dicarbonyl substituted-1-alkenes and methods for their preparation
US10428177B2 (en) 2016-06-03 2019-10-01 Sirrus, Inc. Water absorbing or water soluble polymers, intermediate compounds, and methods thereof
US10196481B2 (en) 2016-06-03 2019-02-05 Sirrus, Inc. Polymer and other compounds functionalized with terminal 1,1-disubstituted alkene monomer(s) and methods thereof
US9617377B1 (en) 2016-06-03 2017-04-11 Sirrus, Inc. Polyester macromers containing 1,1-dicarbonyl-substituted 1 alkenes
US9567475B1 (en) 2016-06-03 2017-02-14 Sirrus, Inc. Coatings containing polyester macromers containing 1,1-dicarbonyl-substituted 1 alkenes
CN106501472A (zh) * 2016-11-29 2017-03-15 昆明理工大学 一种基于抗凝血生化指数评价三七活血作用的方法
CN111018734B (zh) * 2019-12-13 2020-12-22 福建海西新药创制有限公司 一种盐酸西那卡塞中间体的合成方法
WO2023223296A1 (en) * 2022-05-20 2023-11-23 Radius Health, Inc. Process of making abaloparatide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269422D1 (en) * 1981-09-25 1986-04-03 Wellcome Found Pharmaceutical amides, and preparation, formulations and use thereof
AU8868991A (en) * 1990-11-15 1992-06-11 Pentapharm Ag Meta-substituted phenyl alanine derivatives
CZ245994A3 (en) 1993-02-10 1995-10-18 Pentapharm Ag Piperazides of substituted phenylalanine derivatives as thrombin inhibitors
EE03973B1 (et) * 1994-04-26 2003-02-17 Selectide Corporation Faktori Xa inhibiitorid
WO1996005189A1 (de) * 1994-08-09 1996-02-22 Pentapharm Ag Neue inhibitoren vom benzamidintyp
NZ324159A (en) * 1995-12-20 1999-07-29 Hoechst Marion Roussel Inc Process for preparing n-acetyl-(l)-4-cyanophenylalanine ac-(l)-phe(4-cn)-oh and n-acetyl-(l)-p-amidinophenylalanine-cyclohexylglycine-beta-(3-n-methylpyr idinium)-alanine ac-(l)-paph-chg-palme(3)-nh2
DE69823178T2 (de) * 1997-05-02 2005-06-23 Akzo Nobel N.V. Serine protease inhibitoren
US6037356A (en) * 1997-11-26 2000-03-14 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
PL195682B1 (pl) 1997-12-24 2007-10-31 Sanofi Aventis Deutschland Pochodne indolu, sposób ich wytwarzania, środek farmaceutyczny oraz zastosowanie pochodnych indolu
JP3283485B2 (ja) * 1998-04-10 2002-05-20 日本たばこ産業株式会社 アミジン化合物
ID29979A (id) * 1999-01-02 2001-10-25 Aventis Pharma Gmbh Turunan asam malonat baru, proses pembuatannya, penggunaannya dan komposisi sediaan farmasi yang mengandung bahan tersebut (penghambatan aktivitas faktor xa)
CZ20012378A3 (cs) 1999-01-02 2001-09-12 Aventis Pharma Deutschland Gmbh Deriváty arylalkanoylu, způsoby jejich přípravy, použití a farmaceutické přípravky obsahující tyto deriváty
EP1016663A1 (de) * 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Neue Malonsäure Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung und pharmazeutische Zusammensetzungen sie enthaltend (Inhibierung der Faktor Xa Aktivität)

Also Published As

Publication number Publication date
AR027533A1 (es) 2003-04-02
NO20024040L (no) 2002-09-24
EP1265867B1 (de) 2005-12-28
CA2400871A1 (en) 2001-08-30
AU2001235486A1 (en) 2001-09-03
HUP0300080A3 (en) 2004-07-28
CZ20022862A3 (cs) 2002-11-13
HUP0300080A2 (hu) 2003-06-28
NO20024040D0 (no) 2002-08-23
RU2002125671A (ru) 2004-01-10
ES2254370T3 (es) 2006-06-16
US6794365B2 (en) 2004-09-21
ZA200206581B (en) 2003-07-28
MXPA02007398A (es) 2002-12-09
HK1052696A1 (zh) 2003-09-26
DE60116272D1 (de) 2006-02-02
PL357183A1 (en) 2004-07-26
US20020022596A1 (en) 2002-02-21
IL151459A0 (en) 2003-04-10
EP1265867A1 (de) 2002-12-18
CN1406226A (zh) 2003-03-26
JP2003524001A (ja) 2003-08-12
KR20020079892A (ko) 2002-10-19
NZ520982A (en) 2004-05-28
DE60116272T2 (de) 2006-08-17
BR0108694A (pt) 2002-12-10
WO2001062735A1 (en) 2001-08-30
EP1127884A1 (de) 2001-08-29
CA2400871C (en) 2011-04-26

Similar Documents

Publication Publication Date Title
ATE314350T1 (de) Malonsäure derivate, verfahren zu ihrer herstellung, ihre verwendung als inhibitor der faktor xa aktivität und pharmazeutische zusammensetzungen diese enthaltend
ATE252562T1 (de) Pyrazolcarbonsäurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE602004029236D1 (de) Cyclische harnstoffderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung als kinaseinhibitoren
ATE438645T1 (de) 7-phenylamino-4-chinolon-3-carbonsäure-derivate verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE344034T1 (de) N-adamantylmethyl-derivate und zwischenprodukte als pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung
ATE388944T1 (de) Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel, zwischenprodukten und verfahren zur herstellung
ATE265424T1 (de) Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE502004011957D1 (de) Neue cyanopyrrolidide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE50211685D1 (de) Carbonsäureamid substituierte phenylharnstoffderivate, verfahren zu ihrer herstellung als arzneimittel
DE10393704D2 (de) Nancomposite, Verfahren zu ihrer Herstellung und ihre Verwendung
DE602004007226D1 (de) Monomethylderivate von Malonsäure und Verfahren zu ihrer Herstellung
ATE348609T1 (de) Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
ATE472548T1 (de) Substituierte hexahydro-pyrazino(1,2-a)pyrimidin- 4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE60336264D1 (de) Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel sowie zwischenprodukte und methoden zu ihrer herstellung
ATE327981T1 (de) Arylisoxazolin-derivative, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel
ATE323092T1 (de) Pyridopyrimidinon-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE10347385A1 (de) Umgelagerte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
ATE337317T1 (de) Imidazopyrin-derivate, verfahren zu ihrer herstellung and sie enthaltende pharmazeutische zusamensetzungen
DE50212938D1 (de) Derivate von c2-substituierten indan-1-ol-systemen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE323097T1 (de) Neue 5-thio-ss-d-xylopyranosidderivate, verfahren zu deren herstellung, diese enthaltende pharmazeutische zusammensetzungen und deren therapeutische verwendung
DE60004353D1 (de) Derivate der gymnemischen säure, verfahren zu ihrer herstellung und ihre verwendung als medikamente
DE60304703D1 (de) Neue 3-(4-oxo-4h-chromen-2-yl)-(1h)-quinolin-4-one-derivate; verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
ATE538086T1 (de) Cycloalkyl substituierte alkansaürederivate, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel
DE50213487D1 (de) C2-substituierte indan-1-ole und ihre derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE59911949D1 (de) Substituierte sulfonylcyanamide, verfahren zu ihrer herstellung und ihre verwendung als medikament

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties